Small molecule inhibitors of gut microbial choline trimethylamine lyase activity protect against obesity.

After myocardial infarction, gut microbiota affects platelet aggregation rate by regulating the absorption and metabolism of ticagrelor.

The density of the gut microbiota influences the host immune system and adiposity, and can be therapeutically manipulated.

The gut microbiota of East Asians is distinct, dissociated from body mass, and self-sustains compared to White subjects from the same region, and therein may underpin a key health disparity.

Overlapping action of type I, II, and III interferons maintains microbiome homeostasis, prevents IL-17-driven myeloproliferative disease, and protects against inflammatory bowel disease.

Gut microbiota can influence mPFC transcriptional profiles and myelin content, overriding the impact of genetic background in the development of social avoidance behavior.

Chi3l1 binds to bacterial peptidoglycan, helping anchor and organize bacteria within the mucus layer.

Indomethacin, a nonsteroidal anti-inflammatory drug, alters the composition of the intestinal microbiota, and the intestinal microbiota affect the pharmacokinetics of indomethacin.

High-throughput droplet-based cultivation of gut microbes reduces biases of traditional cultivation strategies and thereby enables detection of difficult-to-culture organisms, which is required in applications such as antibiotic screening.

Gut microbiota dysbiosis increased Nos2 expression through the 'gut–lung axis', and altered intracellular antimicrobial and anti-inflammatory environment by abnormal NO, ROS, and Defb1, thereby promoting Mycobacteria colonization in mouse lungs.